Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited announced promising results from its Phase 1b trial of azer-cel, an allogeneic CD19 CAR T therapy for relapsed DLBCL. The trial showed a 75% overall response rate, with 6 complete responses and 3 partial responses, highlighting azer-cel’s potential in patients who have failed multiple lines of therapy. The company plans to meet with the US FDA in late 2025 to discuss a pivotal trial, indicating significant progress in addressing high-unmet-need populations.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company specializes in creating off-the-shelf CAR T-cell therapies, particularly targeting aggressive blood cancers like diffuse large B-cell lymphoma (DLBCL).
YTD Price Performance: -66.22%
Average Trading Volume: 552,721
Technical Sentiment Signal: Sell
Current Market Cap: A$93.35M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.